TOP HEADLINES

Featured Story

Asterias, Cancer Research UK partner on lung cancer vaccine trial

Asterias Biotherapeutics, a subsidiary of California-based BioTime, is teaming up with nonprofit Cancer Research UK to trial an immunotherapy vaccine to treat patients with non-small cell lung cancer.

Takeda reorg preps vaccines unit for emerging markets test

As promised, newcomer COO Christophe Weber is shaking things up at Takeda Pharmaceutical, with the Japanese company this week rolling out a revamped organizational structure that it hopes will make it the "best-in-class company in every aspect" of its business. And that includes vaccines.

Protein Sciences nabs stake in diabetes vax developer Diamyd

With its candidate diabetes vaccine in Phase II combo studies, Diamyd Medical is seeing some new investment--including a bumped-up agreement with longtime partner Protein Sciences.

AstraZeneca sends James Van Der Beek 'camping' to promote FluMist Quadrivalent

To get the word out on AstraZeneca's needle-free FluMist Quadrivalent vaccine, the company has brought on James Van Der Beek--of "Dawson's Creek" fame--to participate in its "Insist on the Mist" campaign.

Immunotherapy vaccine combo cuts recurrence in HER2 breast cancer patients

A new breast cancer vaccine tested in a clinical trial at the University of Texas MD Anderson Cancer Center boosted survival rates in patients with elevated levels of a protein associated with cancer growth, a new study shows.

MORE NEWS

From Our Sister Sites

FierceBiotechIT

AstraZeneca is following the well-trodden path of offshoring part of its IT to India. But unlike some of its peers--and in a reversal of its own strategy--the Big Pharma is adding in-house capacity and lessening its reliance on IT service providers.

FierceBiotechIT

With clinical trial sponsors spending a sizable chunk of their huge Phase III trial budgets on source data verification in return for questionable benefits, risk-based monitoring is an obvious target for TransCelerate BioPharma's R&D efficiency agenda. The Big Pharma consortium has further clarified its thinking on the topic in two research papers.